Clinical research and Phase 1 studies have already shown encouraging results which suggests that TPA can be effectively used in the treatment of relapsed/refractory acute myeloid leukemia (AML). However, to confirm these results, further research is needed. Before undergoing these new tests AML patients must understand the investigative nature of the Phase 2 TPA studies in the cure of these terminal diseases. Only patients with a type of AML for which there is no standard therapy, can participate in the study. For full information on all criteria needed to be met and the documents needed to be presented, please contact the study leading medical professional dr. Roger Strair, M.D. PhD, at The Cancer Institute of New Jersey (CINJ).
